Beyond the Data: Translating CLL Evidence into Pharmacist-Led Recommendations

Meeting Objectives:

• • Briefly review clinical evidence, and discuss triggers that signal a need to initiate, modify, or switch CLL therapy
  • Discuss patient-specific treatment recommendations by integrating disease genomics, comorbidities, and concomitant medications into regimen selection
  • Apply monitoring parameters and strategies to proactively manage safety across BTKi-based regimens
  • Discuss care as a whole, addressing practical barriers such as formulary access, prior authorization, and multidisciplinary care coordination across treatment settings